RhumbLine Advisers
KBIO

RhumbLine Advisers’s KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) KBIO Stock Holding History

RhumbLine Advisers’s Portfolio KBIO Stock Details KBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-1,253
Closed -$57K – 3039
2013
Q2 		$57K Buy
+1,253
New +$56.8K ﹤0.01% 3289

Other funds holding KBIO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LBH
Lehman Brothers Holdings New York $794K AUM 28.79% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

RhumbLine Advisers's KBIO Position: Q3 2013 in Review

RhumbLine Advisers sold out of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) in Q3 2013, closing a stake of 1,253 shares — an estimated $57K sold.

RhumbLine Advisers first reported a position in KBIO in Q2 2013 and held it in 1 quarter. The position peaked at $57K in Q2 2013. 50 funds tracked by Wall St. Rank hold KBIO as of Q3 2013.

  • RhumbLine Advisers reported no remaining KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position as of Q3 2013 after selling out during the quarter.
  • RhumbLine Advisers sold 1,253 KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) shares in Q3 2013, an estimated $57K.
  • RhumbLine Advisers first reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in Q2 2013 and held it in 1 quarter.
  • RhumbLine Advisers's KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) position peaked at $57K in Q2 2013.
  • 50 funds tracked by Wall St. Rank held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) as of Q3 2013.

Based on RhumbLine Advisers's 13F filing for Q3 2013, filed 5 Nov 2013.